Abstract
The influence of carbon metabolism on oxidative phosphorylation is poorly understood in mycobacteria. M. tuberculosis expresses two respiratory terminal oxidases, the cytochrome bc1:aa3 and the cytochrome bd oxidase, which are jointly required for oxidative phosphorylation and mycobacterial viability. The essentiality of the cytochrome bc1:aa3 for optimum growth is illustrated by its vulnerability to chemical inhibition by the clinical drug candidate Q203 and several other chemical series. The cytochrome bd oxidase is not strictly essential for growth but is required to maintain bioenergetics when the function of the cytochrome bc1:aa3 is compromised. In this study, we observed that the potency of drugs targeting the cytochrome bc1:aa3 is influenced by carbon metabolism. The efficacy of Q203 and related derivatives was alleviated by glycerol supplementation. The negative effect of glycerol supplementation on Q203 potency correlated with an upregulation of the cytochrome bd oxidase-encoding cydABDC operon. Upon deletion of cydAB, the detrimental effect of glycerol on the potency of Q203 was abrogated. The same phenomenon was also observed in recent clinical isolates, but to a lesser extent compared to the laboratory-adapted strain H37Rv. This study reinforces the importance of optimizing in vitro culture conditions for drug evaluation in mycobacteria, a factor which appeared to be particularly essential for drugs targeting the cytochrome bc1:aa3 terminal oxidase.
Subject terms: Tuberculosis, Antimicrobials
Introduction
Mycobacterium tuberculosis is a heterotrophic bacterium capable of deriving energy from a wide array of carbon sources when grown in artificial culture broth media1–5. Yet, constraints imposed by the host restrict access to certain nutrients, forcing M. tuberculosis to use a limited pool of carbon sources as energy supplies, mainly in the form of lipids, and probably lactate6–8. While the glycolytic pathway is dispensable for virulence in animals9, gluconeogenesis is required for growth and persistence10. Remarkably, mycobacteria deficient for gluconeogenesis are unable to establish infection and are cleared from the host at a very fast rate5,10. Nevertheless, mycobacteria are still able to scavenge a limited amount of host-derived glucose used primarily as a precursor for biosynthetic pathway rather than for energy production11. It is interesting to note that the absence of catabolic repression in mycobacteria allow the bacteria to co-metabolize several carbon sources12, a property that may confer a survival advantage in an environment in which resources are scarce such as in the lung granuloma13. NAD+ is a crucial cofactor involved in redox cellular balance, catabolism and energy production14. When carbohydrates are provided as carbon and energy source, NAD+ is reduced to NADH by glycolytic enzymes, which is in turn re-oxidized back either by the respiratory NADH dehydrogenases, or by fermentative enzymes15. Carbon and energy metabolism are tightly regulated in bacteria. Even though ATP is the central energy currency in all bacteria, strategies to resynthesize it can differ significantly from one bacterium to the next. Many bacteria including enterobacteria are able to bypass the essentiality of the oxidative phosphorylation pathway when grown on carbohydrates, doing so by regenerating the NAD+ pool by fermentation16,17. Mycobacteria are unable to do so either in culture broth media or in animal models. The absence of fermentative (NADH-dependent) lactate dehydrogenase in M. tuberculosis makes the oxidative phosphorylation pathway strictly essential for growth18. This is illustrated by the successful clinical development of bedaquiline (Sirturo®), a drug targeting the FOF1 ATP synthase19–21. Since drugs targeting the Electron Transport Chain are effective against phenotypic drug-resistant mycobacteria22, they could be of value to shorten TB treatment time. In addition of the FOF1 ATP synthase, type II NADH dehydrogenases23,24, the menaquinone biosynthetic pathway25,26, and the cytochrome bc1:aa3 terminal oxidase27–29 are chemically-validated drug targets in M. tuberculosis. The qcrB subunit of the cytochrome bc1:aa3 is the target of the clinical drug candidate Q20329, as well as numerous other chemical series27–29. Despite a central role in metabolism and host adaptation, it is still largely unknown how carbon catabolism is coupled to oxidative phosphorylation in mycobacteria. Here we show that the potency of drugs targeting the cytochrome bc1:aa3 are modulated by carbon catabolism and the composition of the culture broth medium. Glycerol supplementation in the widely used 7H9 broth medium had a detrimental effect on the potency of the imidazopyridine carboxamide Q203 and ND-1088530, another in vivo active imidazopyridine carboxamide under study. This phenomenon was explained by a significant up-regulation of the Cyt-bd terminal oxidase that diminishes the potency of cytochrome bc1:aa3 inhibitors by providing an alternate respiratory route.
Results and Discussion
Glycerol supplementation interferes with the potency of drugs targeting the Cyt-bc1:aa3 in mycobacteria
Despite the discovery of multiple chemical classes targeting the cytochrome bc1:aa3, there are some conflicting reports on the consequences of chemical inhibition of the target on growth inhibition under laboratory conditions31–33, as well as reported difficulties to isolate escape mutants34. We hypothesised that conditions used to test drug potency may influence apparent activity. Since glycerol supplementation in 7H9-based medium is one of the parameters that varies widely between laboratories, and a factor known to influence drug potency35, we tested the efficacy of Q203 in 7H9 culture broth medium with and without glycerol in a turbidity-based assay. The Minimum Inhibitory Concentration inhibiting 50% of the growth (MIC50) were comparable after 5 or 8 days of incubation. However, maximum growth inhibition was not achieved in the presence of glycerol (Fig. 1A,B), suggesting that Q203 treatment was growth-retarding but not bacteriostatic in glycerol-supplemented medium. This phenomenon was also observed with ND-10885, a preclinical drug candidate targeting the cytochrome bc1:aa330 (Fig. 1C,D). In comparison, the maximum growth inhibition of bedaquiline was not affected by the presence of glycerol (Fig. 1E,F).
Since the classical 7H9-ADS-tween 80 medium provides several potential energy and carbon sources, we profiled the potency of Q203 in a home-made 7H9-base medium containing either glycerol, glucose, pyruvate, acetate or propionate as dominant carbon sources. As a control, we showed that mycobacteria multiplied very minimally on the base medium without any dominant carbon sources (Fig. S1). Results confirmed that glycerol metabolism has a detrimental effect on the potency of Q203, both in M. tuberculosis H37Rv and in M. bovis BCG. Indeed, the drug candidate was unable to inhibit mycobacterial growth, as witnessed by the high value of the bottom plateau on glycerol (Figs 2A and S2A). We also observed that the MIC50 value of Q203 was the highest in glycerol medium and the lowest on propionate and acetate medium (Table S1). On all carbon sources except glycerol, Q203 and ND-10885 inhibited mycobacterial growth as well as bedaquiline or moxifloxacin (Fig. 2D–G). Quantification of extracellular glycerol concentration over a period of 12 days revealed that Q203-treated mycobacteria consumed glycerol efficiently, confirming the absence of growth inhibition of the drug candidate on this carbon source (Fig. S3A). Incidentally, we also observed that the MIC50 values of bedaquiline varied as a function of the carbon source, but maximum growth inhibition was achieved in all culture broth media (Fig. 2B, Table S1). The detrimental effect of glycerol supplementation on the potency of Cyt-bc1:aa3 inhibitors was also apparent on 7H10 agar plates. Q203 at 100 nM was unable to inhibit mycobacterial growth on 7H10 agar plates supplemented with glycerol after 18 days of incubation, whereas it was potent on 7H10 agar plates supplemented with pyruvate (Fig. 3A).
Q203 treatment in glycerol-supplemented medium induces the overexpression of the cydABDC operon
Given the synthetic lethal interaction between the terminal oxidases in mycobacteria31,36, we hypothesized that overexpression of either of the terminal oxidases could explain the glycerol phenomenon. Therefore, we monitored the expression of the qcrCAB and cydABDC operon in mycobacteria growing in 7H9 medium with or without glycerol. After overnight culture in broth medium without glycerol, M. bovis BCG was transferred to fresh 7H9 medium with or without 0.2% glycerol supplement, and exposed to 100 nM of Q203 or DMSO control. After 72 hours of incubation, RNAs were extracted and the relative abundance of the terminal oxidases-encoding genes were evaluated by quantitative RT-PCR. Results revealed that glycerol supplementation, or Q203 treatment, had limited effect on the expression of the qcrCAB operon (Table 1). Conversely, glycerol supplementation, or Q203 treatment, triggered a 2- to 3-fold increase in expression of the cydABDC operon, whereas the combination of both stimulated a 7- to 8-fold induction (Table 1). These results suggested that the induction of the Cyt-bd expression on glycerol-supplemented 7H9 medium provided an efficient alternate pathway for the electron transport chain, thereby diminishing the potency of Q203 and related drugs. This idea was supported by the finding that over-expression of the cydABDC operon on a multi-copy plasmid partially diminished partially the growth inhibition potency of Q203 on acetate-supplemented 7H9 medium (Fig. S4).
Table 1.
Genes | Expression level (Fold change) | |||
---|---|---|---|---|
−Glycerol | +Glycerol | |||
− | +Q203 | − | +Q203 | |
cydA | 1.0 | 2.7 ± 0.7 | 2.2 ± 0.1 | 8.1 ± 0.2 |
cydB | 1.0 | 2.9 ± 0.4 | 2.2 ± 0.2 | 7.4 ± 0.3 |
qcrC | 1.0 | 0.8 ± 0.4 | 0.5 ± 0.1 | 1.4 ± 0.4 |
qcrA | 1.0 | 0.75 ± 0.4 | 0.47 ± 0.1 | 1.01 ± 0.5 |
qcrB | 1.0 | 0.90 ± 0.3 | 0.50 ± 0.1 | 1.31 ± 0.6 |
Expression levels were measured by qRT-PCR. The gene sigA was used as an endogenous control (housekeeping gene) to determine the relative expression of the M. bovis qcrCAB and cydAB operons in culture broth media supplemented with glycerol and/or Q203.
It was also observed that the mycobacteria basal Oxygen Consumption Rate (OCR) on glycerol supplemented medium was significantly increased after treatment with Q203 for 48 hours (Fig. 4A,B). This result suggests that chemical inhibition of the Cyt-bc1:aa3 terminal oxidase stimulates respiration through the Cyt-bd branch.
The carbon source-dependency of the Cyt-bc1:aa3 inhibitors is alleviated upon cydAB deletion
To verify this assumption, the potency of Q203 was tested against the strains M. tuberculosis H37RvΔcydAB and BCGΔcydAB that do not express Cyt-bd36. Results revealed that maximum growth inhibition was achieved against the mutant strain, irrespective of glycerol supplementation (Fig. S5A). Reintroduction of a functional cydAB copy in the strain H37RvΔcydABcomp36 restored the phenotype (Fig. S5C). These results were extended to defined culture broth media containing unique dominant carbon sources. Results confirmed that the potency of Q203 and the related drug ND-10885 was not influenced by carbon metabolism in the H37Rv ΔcydAB strain (Fig. 5D,E). In the absence of a functional Cyt-bd, the MIC50 of Q203 was shifted toward the lowest values previously obtained against the parental strains replicating on propionate (Figs 5A, S2C, Table S2). In comparison, the MIC values of bedaquiline were not affected by the absence of a functional Cyt-bd (Figs 5B, S2D, Table S2). Furthermore, growth of the H37Rv ΔcydAB strain was completely inhibited by Q203, even when glycerol was provided as sole carbon source (Fig. 5D), and to the same extent observed with bedaquiline (Fig. 4F) or moxifloxacin (Fig. 5G). These results demonstrated that the electron flow to the mycobacterial respiratory oxidases is modulated by carbon metabolism and influences the potency of the clinical candidate Q203. When tested on glycerol-supplemented agar plates, Q203 inhibited the growth of the H37Rv ΔcydAB strain as efficiently as bedaquiline (Fig. 5H).
Glycerol metabolism interferes with the selection of spontaneous resistant mutants to Q203
We reasoned that the detrimental effect of glycerol metabolism may be the reason behind the reported difficulty to select escape mutants resistant to qcrB inhibitors34. In our own experience, spontaneous mutants resistant to Q203 could only be obtained at very high drug concentration29 and picked between day 12 and 14, before a lawn would appear on the plates (unpublished observation). To test this hypothesis, selection of escape mutants resistant to Q203 was attempted in the BCG parental and ΔcydAB strains on glycerol- or pyruvate-supplemented agar plates. 3 × 108 bacilli were plated on agar plates containing Q203 at 500 nM and 100 nM. Visual examination of the plates after eighteen days of incubation at 37 °C revealed a thick lawn when the parental strain was plated on the glycerol plates (Table S3). Conversely, individual colonies were observed on the plates containing Q203 on pyruvate-supplemented plates (Table S3), showing that escape mutants to Cyt-bc1:aa3 inhibitors is facilitated by the omission of glycerol supplementation. Among all conditions tested, the easiest way to select spontaneous-resistant mutants was in the ΔcydAB background. Indeed, in the absence of a functional Cyt-bd, escape mutants to Q203 could be obtained at a frequency in the range 4.3 × 10−8 to 8.7 × 10−8, at a drug concentration as low as 5 nM, irrespective of the presence of glycerol (Table S3). Resistance to Q203 correlated with a single-nucleotide polymorphism in qcrB in all the mutants that were analysed (Table S3).
The potency of Q203 is less affected by glycerol supplementation in M. tuberculosis clinical isolates
Lastly, we were interested in testing if the negative influence of glycerol supplementation was restricted to the laboratory-adapted M. tuberculosis strain H37Rv, or could be extended to recent clinical isolates. The growth kinetics presented on Fig. 2D was repeated in the clinical strains N0145, N0155, N0153, N0157 and N005237–39. We noted that the glycerol effect was still noticeable on the clinical isolates, but the phenotype was very less pronounced compared to H37Rv (Fig. 6). This result points to an abnormal deregulation of the cydABDC operon in M. tuberculosis H37Rv, as reported previously31, and in M. bovis BCG. RT-PCR analysis confirmed a reduced expression of the cydABDC operon in the clinical isolates used in this study compared to H37Rv (Table 2).
Table 2.
Clinical isolates # | Fold change in expression relative to H37Rv | |
---|---|---|
cydA | cydB | |
N0153 | 0.64 ± 0.02 | 0.63 ± 0.02 |
N0157 | 0.59 ± 0.05 | 0.58 ± 0.04 |
N0052 | 0.35 ± 0.08 | 0.41 ± 0.1 |
N0155 | 0.31 ± 0.02 | 0.32 ± 0.02 |
N0145 | 0.15 ± 0.01 | 0.16 ± 0.02 |
RNA was extracted from early log-phase standing cultures growing in 7h9 liquid broth medium. Gene expression was normalized relative to H37Rv, sigA gene was used as an endogenous control.
Several lessons can be drawn from this study. It is first a reminder that despite its attractiveness, drug development against bacterial central metabolism and energetics targets is complex since the essentiality of those targets may be conditional and influenced by multiple factors such as the composition of the culture broth medium40. Developing screening conditions that reflect at least some of the conditions encountered by the bacteria during infection is primordial. Since glycerol metabolism does not seem to be relevant during infection35, we suggest that it should be omitted from the 7H9-based medium when screening or developing novel anti-TB drugs, which is particularly important for drugs targeting oxidative phosphorylation. The study also highlights possible biases that may be introduced by using laboratory strains expressing abnormal Cyt-bd level. In the quest of developing a drug combination targeting both terminal oxidases, we suggest that recent clinical isolates should be used alongside the laboratory-adapted strain H37Rv to guide chemical optimization and mode of action studies of drugs targeting the Cyt-bc1:aa3. Furthermore, the observation made in M. tuberculosis H37Rv suggests that a deregulation of the Cyt-bd expression could be a mechanism triggering resistance to drugs targeting the Cyt-bc1:aa3. This is a consideration that should be kept in mind as Q203 is entering into clinical phase 2 proof of concept studies41.
Materials and Methods
Strains and growth conditions
M. tuberculosis and derivative strains were maintained in Middlebrook 7H9 broth medium supplemented with 0.2% glycerol, 0.05% Tween 80, and 10% Album-Dextrose-Saline (ADS) supplement. Hygromycin (80 μg/mL) was used when required. The defined medium was based on 7H9 medium with the omission of glucose, tween 80 (replaced by Tyloxapol 0.05%) and BSA fraction V (substituted by 0.1% fatty-acid free BSA). All carbon sources were used at 0.2% except propionate and pyruvate which were used at 0.1% and 20 mM respectively. Q203 and bedaquiline (BDQ) were custom made at GVK Bio, moxifloxacin was purchased from Sigma and ND-10885 was synthesized as described before30.
All the activities pertaining to M. tuberculosis were performed in a registered Biosafety Level 3 facility, whereas the work on M. bovis (BCG) was carried out in a licensed Biosafety Level 2 facility.
MIC50 determination
MIC50 were determined as previously described, with slight modifications. Briefly, drugs dissolved in 90% DMSO were twofold serial-diluted in duplicates and spotted to 96-well flat bottom plates. A volume of 200 µl of M. tuberculosis H37Rv culture (OD600 0.005) was dispensed into 96 well flat bottom plates and the assay plates were incubated at 37 °C. Growth was determined by recording absorbance at 600 nm (OD600) on BioTek Cytation multimode reader after 5, 8 and 10 days of incubation. Absorbance values (OD600) were plotted using GraphPad Prism version 6 software and MIC50 were calculated from the curves obtained35,36.
Growth inhibition assays on agar plates
Growth of M. tuberculosis was compared using a quadrant plate in presence and absence of Q203 on Middlebrook 7H10-OADC agar plates supplemented either with glycerol (0.5%) or pyruvate (20 mM). In brief, 50 µl of a suspension of 106 mycobacteria was plated on each quadrant plates. Mycobacterial growth was observed after two to three weeks of incubation at 37 °C42.
Growth kinetic assays
M. tuberculosis was first grown to mid-log phase in 7H9 liquid media supplemented with 10% ADS supplement, 0.2% glycerol and 0.05% of tween 80, washed twice in 7H9 base medium supplemented with 0.05% tyloxapol, without carbon sources, and re-suspended in the same medium. The cells were inoculated at an initial OD600 of 0.005 in 7H9 liquid broth medium supplemented with 0.1% fatty acid free BSA, 0.8% NaCl, and glucose, glycerol, pyruvate, acetate, or propionate as sole carbon source at the concentrations mentioned above. Bacterial growth was monitored at OD600 over time using an Eppendorf’s Biophotometer plus spectrophotometer.
RT-PCR
Cells from mid-log phase culture of M. bovis (BCG) were washed and inoculated at an initial OD600 of 0.2 in 7H9 liquid media (10% ADS and 0.05% of tween 80) supplemented with and without 0.2% glycerol. Bacterial cultures in their respective media were incubated at 37 °C for 72 hrs in presence and absence of Q203. Total RNA was extracted using Max Bacterial Enhancement Reagent and TRIZOL® according to manufacturer’s instruction (Ambion). Cell lysis was achieved by vigorous vortexing for 10 minutes using Disruptor Genie (Scientific Industries), following by DNase (TURBO DNA-free kit, Ambion) treatment. RNA concentrations were determined with a NanoDrop 2000c spectrophotometer.
First strand cDNA was synthesized from 1 µg of RNA for each sample using qScript cDNA Supermix (Quanta Biosciences). cDNA was used as a template and Real time PCR was performed using KAPA SYBR Fast qPCR master mix (Sigma) according to manufacturer’s instructions in Step One Plus Real Time PCR system (Applied Biosystems). Primers for RT-PCR were designed using Primer 3 software (Table S4). Results were normalized to sigA as an endogenous control13.
Oxygen consumption rate measurements
Mid-log phase cultures of M. bovis (BCG) were washed and inoculated at an initial OD600 of 0.2 in 7H9 liquid broth media supplemented with and without 0.2% glycerol. Bacterial cultures in their respective media were incubated at 37 °C for 48 hrs in presence or absence of Q203. Cells were harvested by centrifugation and re-suspended in their respective culture broth medium. The basal oxygen consumption rates (OCR) of M. bovis BCG were measured using the Seahorse XFe96 Analyzer (Agilent). 7 × 106 cells were added to each well on the Agilent Seahorse cell culture microtiter plates coated with 22.4 µg/mL Cell Tak. The cells were adhered to the bottom of the plate by centrifugation. The OCR data points were derived from 4 minutes of continuous measurements. The representative basal OCR was an average of 6 measurements. The experiment concluded with an injection of CCCP (2 µM), followed by 5 additional measurement points. All data are expressed as the mean and error of triplicates, calculated using the Wave Desktop 2.2 software43.
Supplementary information
Acknowledgements
This work was supported by the Singapore Ministry of Health’s National Medical Research Council under its Cooperative Basic Research Grant (Project Award NMRC/CBRG/0083/2015), and the Lee Kong Chian School of Medicine, Nanyang Technological University Start-Up Grant (K.P.). BSL is supported by a Nanyang President’s Graduate Scholarship. Support from the NIH grant 5R37AI054193 (MJM, GCM) is gratefully acknowledged.
Author Contributions
K.P. and N.P.K. designed the research; N.P.K., B.S.L. and N.B.A.R., performed the experiments; G.C.M. and M.J.M. designed and synthesized the compounds; K.P., N.P.K., G.C.M. and M.J.M. analysed data; K.P. wrote the paper with contribution from the other authors.
Competing Interests
The authors declare no competing interests.
Footnotes
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary information accompanies this paper at 10.1038/s41598-019-44887-9.
References
- 1.Segal W, Bloch H. Biochemical differentiation of mycobacterium tuberculosis grown in vivo and in vitro. J. Bacteriol. 1956;72(2):132–141. doi: 10.1128/jb.72.2.132-141.1956. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Muñoz-Elías EJ, McKinney JD. Carbon metabolism of intracellular bacteria. Cell Microbiol. 2006;8(1):10–22. doi: 10.1111/j.1462-5822.2005.00648.x. [DOI] [PubMed] [Google Scholar]
- 3.Russell DG, et al. Mycobacterium tuberculosis wears what it eats. Cell Host Microbe. 2010;8(1):68–76. doi: 10.1016/j.chom.2010.06.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Zimmermann M, et al. Integration of Metabolomics and Transcriptomics Reveals a Complex Diet of Mycobacterium tuberculosis during Early Macrophage Infection. mSystems. 2017;2(4):e00057–17. doi: 10.1128/mSystems.00057-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S. Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc. Natl. Acad. Sci. USA. 2010;107(21):9819–9824. doi: 10.1073/pnas.1000715107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Lee W, VanderVen BC, Fahey RJ, Russell DG. Intracellular Mycobacterium tuberculosis Exploits Host-derived Fatty Acids to Limit Metabolic Stress. J. Biol. Chem. 2013;288(10):6788–6800. doi: 10.1074/jbc.M112.445056. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Griffin JE, et al. Cholesterol Catabolism by Mycobacterium tuberculosis Requires Transcriptional and Metabolic Adaptations. Chem. Biol. 2012;19(2):218–227. doi: 10.1016/j.chembiol.2011.12.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Billig S, et al. Lactate oxidation facilitates growth of Mycobacterium tuberculosis in human macrophages. Sci. Rep. 2017;7:6484. doi: 10.1038/s41598-017-05916-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Phong WY, et al. Characterization of Phosphofructokinase Activity in Mycobacterium tuberculosis Reveals That a Functional Glycolytic Carbon Flow Is Necessary to Limit the Accumulation of Toxic Metabolic Intermediates under Hypoxia. PLoS One. 2013;8(2):e56037. doi: 10.1371/journal.pone.0056037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Muñoz-Elías EJ, McKinney JD. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat. Med. 2005;11(6):638–644. doi: 10.1038/nm1252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Marrero J, Trujillo C, Rhee KY, Ehrt S. Glucose Phosphorylation Is Required for Mycobacterium tuberculosis Persistence in Mice. PLoS Pathog. 2013;9(1):e1003116. doi: 10.1371/journal.ppat.1003116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.de Carvalho LPS, et al. Metabolomics of Mycobacterium tuberculosis Reveals Compartmentalized Co-Catabolism of Carbon Substrates. Chem. Biol. 2010;17(10):1122–1131. doi: 10.1016/j.chembiol.2010.08.009. [DOI] [PubMed] [Google Scholar]
- 13.Berney M, Cook GM. Unique Flexibility in Energy Metabolism Allows Mycobacteria to Combat Starvation and Hypoxia. PLoS One. 2010;5(1):e8614. doi: 10.1371/journal.pone.0008614. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Rodionova IA, et al. Metabolic and Bactericidal Effects of Targeted Suppression of NadD and NadE Enzymes in Mycobacteria. mBio. 2014;5(1):e00747–1. doi: 10.1128/mBio.00747-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Vemuri GN, Eiteman MA, McEwen JE, Olsson L, Nielsen J. Increasing NADH oxidation reduces overflow metabolism in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA. 2007;104(7):2402–2407. doi: 10.1073/pnas.0607469104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Förster AH, Gescher J. Metabolic Engineering of Escherichia coli for Production of Mixed-Acid Fermentation End Products. Front. Bioeng. Biotechnol. 2014;2:16. doi: 10.3389/fbioe.2014.00016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Clark DP. The fermentation pathways of Escherichia coli. FEMS Microbiol. Lett. 1989;63(3):223–234. doi: 10.1111/j.1574-6968.1989.tb03398.x. [DOI] [PubMed] [Google Scholar]
- 18.Cook, G. M. et al. OXPHOS as a target space for tuberculosis: success, caution, and future directions. Microbiol. Spectr. 5(3), 10.1128/microbiolspec.TBTB2-0014-2016 (2017). [DOI] [PMC free article] [PubMed]
- 19.Andries K, et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis. Science. 2005;307(5707):223–227. doi: 10.1126/science.1106753. [DOI] [PubMed] [Google Scholar]
- 20.Diacon AH, et al. Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. N. Engl. J. Med. 2014;371(8):723–732. doi: 10.1056/NEJMoa1313865. [DOI] [PubMed] [Google Scholar]
- 21.Pym AS, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur. Respir. J. 2016;47(2):564–574. doi: 10.1183/13993003.00724-2015. [DOI] [PubMed] [Google Scholar]
- 22.Rao SPS, Alonso S, Rand L, Dick T, Pethe K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA. 2008;105(33):11945–11950. doi: 10.1073/pnas.0711697105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Harbut MB, et al. Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity. Angew. Chem. Int. Ed. 2018;57(13):3478–3482. doi: 10.1002/anie.201800260. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Murugesan D, et al. 2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure–Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization. ACS Infect. Dis. 2018;4(6):954–969. doi: 10.1021/acsinfecdis.7b00275. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Kurosu M, Crick DC. MenA Is a Promising Drug Target for Developing Novel Lead Molecules to Combat Mycobacterium tuberculosis. Med. Chem. 2009;5(2):197–207. doi: 10.2174/157340609787582882. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Sukheja P, et al. A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells. mBio. 2017;8(1):e02022–16. doi: 10.1128/mBio.02022-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Cleghorn LAT, et al. Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB. J. Med. Chem. 2018;61(15):6592–6608. doi: 10.1021/acs.jmedchem.8b00172. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Chandrasekera NS, et al. Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB. ACS Infect. Dis. 2017;3(12):898–916. doi: 10.1021/acsinfecdis.7b00112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Pethe K, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 2013;19(9):1157–1160. doi: 10.1038/nm.3262. [DOI] [PubMed] [Google Scholar]
- 30.Moraski GC, et al. Imidazo[1,2-a]Pyridine-3-Carboxamides Are Active Antimicrobial Agents against Mycobacterium avium Infection In Vivo. Antimicrob. Agents Chemother. 2016;60(8):5018–5022. doi: 10.1128/AAC.00618-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Arora K, et al. Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2014;58(11):6962–6965. doi: 10.1128/AAC.03486-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Moraski GC, et al. Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity. ACS Med. Chem. Lett. 2011;2(6):466–470. doi: 10.1021/ml200036r. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Foo C, et al. Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis. mBio. 2018;9(5):e01276–18. doi: 10.1128/mBio.01276-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.van der Westhuyzen R, et al. Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration. J. Med. Chem. 2015;58(23):9371–9381. doi: 10.1021/acs.jmedchem.5b01542. [DOI] [PubMed] [Google Scholar]
- 35.Pethe K, et al. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat. Commun. 2010;1:57. doi: 10.1038/ncomms1060. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Kalia NP, et al. Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection. Proc. Natl. Acad. Sci. USA. 2017;114(28):7426–7431. doi: 10.1073/pnas.1706139114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Rose G, et al. Mapping of Genotype–Phenotype Diversity among Clinical Isolates of Mycobacterium tuberculosis by Sequence-Based Transcriptional Profiling. Genome Biol. Evol. 2013;5(10):1849–1862. doi: 10.1093/gbe/evt138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Hershberg R, et al. High Functional Diversity in Mycobacterium tuberculosis Driven by Genetic Drift and Human Demography. PLoS Biol. 2008;6(12):e311. doi: 10.1371/journal.pbio.0060311. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Parwati I, van Crevel R, van Soolingen D. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect. Dis. 2010;10(2):103–111. doi: 10.1016/S1473-3099(09)70330-5. [DOI] [PubMed] [Google Scholar]
- 40.Murima P, McKinney, John D, Pethe K. Targeting Bacterial Central Metabolism for Drug Development. Chem. Biol. 2014;21(11):1423–1432. doi: 10.1016/j.chembiol.2014.08.020. [DOI] [PubMed] [Google Scholar]
- 41.ClinicalTrials.gov. [database on the Internet]. Bethesda (MD): National Library of Medicine (US); 2000. [updated 2018 July 31]. A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203); Identifier NCT03563599. Available from, https://clinicaltrials.gov/ct2/show/NCT03563599?term=NCT03563599&rank=1 (2018).
- 42.Chavadi S, et al. Global Effects of Inactivation of the Pyruvate Kinase Gene in the Mycobacterium tuberculosis Complex. J. Bacteriol. 2009;191(24):7545–7553. doi: 10.1128/JB.00619-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Lamprecht DA, et al. Turning the respiratory flexibility of Mycobacterium tuberculosis against itself. Nat. Commun. 2016;7:12393. doi: 10.1038/ncomms12393. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.